UK NICE recommends use of Verzenios in breast cancer.- Eli Lilly
The UK's NICE has recommended the use of Verzenios (abemaciclib), from Eli Lilly, for locally advanced or metastatic forms of breast cancer in England and Wales when used in combination with an aromatase inhibitor. Verzenios is a CDK4/6 inhibitor which increases the effectiveness of aromatase inhibitors, which tackle tumours by blocking the production of oestrogen.
According to NICE, this therapy is as effective as Ibrance (palbociclib), from Pfizer, and Kisqali (ribociclib), from Novartis, which NICE already recommends as initial hormone therapy for hormone receptor-positive HER2 negative, locally advanced or metastatic breast cancer.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.